Daniel Dolan
2021
In 2021, Daniel Dolan earned a total compensation of $501.4K as Chief Financial Officer at Nabriva Therapeutics AG.
Compensation breakdown
| Non-Equity Incentive Plan | $93,500 |
|---|---|
| Option Awards | $110,000 |
| Salary | $271,250 |
| Other | $26,690 |
| Total | $501,440 |
Dolan received $271.3K in salary, accounting for 54% of the total pay in 2021.
Dolan also received $93.5K in non-equity incentive plan, $110K in option awards and $26.7K in other compensation.
Rankings
In 2021, Daniel Dolan's compensation ranked 10,713th out of 12,406 executives tracked by ExecPay. In other words, Dolan earned more than 13.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,713 out of 12,406 | 14th |
Division Manufacturing | 4,720 out of 5,494 | 14th |
Major group Chemicals And Allied Products | 2,122 out of 2,369 | 10th |
Industry group Drugs | 1,885 out of 2,090 | 10th |
Industry Pharmaceutical Preparations | 1,394 out of 1,537 | 9th |
Source: SEC filing on July 11, 2022.
Dolan's colleagues
We found two more compensation records of executives who worked with Daniel Dolan at Nabriva Therapeutics AG in 2021.